Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$204.46 USD

204.46
507,749

+1.69 (0.83%)

Updated Dec 8, 2023 04:00 PM ET

After-Market: $204.47 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
2Buy17.61%
3Hold8.96%
4Sell4.80%
5Strong Sell2.32%
S&P50010.64%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CRL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 234 241 228 238 195
Receivables 752 643 618 514 472
Notes Receivable 0 0 0 0 0
Inventories 256 199 186 161 128
Other Current Assets 197 191 169 109 102
Total Current Assets 1,439 1,274 1,201 1,021 898
Net Property & Equipment 1,466 1,291 1,124 1,044 933
Investments & Advances 312 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 41 40 38 45 23
Intangibles 3,805 2,792 1,875 1,616 1,320
Deposits & Other Assets 148 1,334 1,074 826 682
Total Assets 7,603 7,024 5,491 4,693 3,856
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 206 198 122 112 66
Current Portion Long-Term Debt 0 3 50 39 31
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 417 475 357 298 244
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 469 357 310 262 216
Total Current Liabilities 1,092 1,033 840 710 558
Mortgages 0 0 0 0 0
Deferred Taxes/Income 216 240 217 167 144
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,708 2,664 1,930 1,850 1,637
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 175 243 205 183 179
Minority Interest (Liabilities) 42 53 26 29 19
Total Liabilities 4,622 4,485 3,373 3,055 2,536
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 0 0
Capital Surplus 1,805 1,718 1,628 1,532 1,448
Retained Earnings 1,433 981 625 280 42
Other Equity -257 -161 -135 -175 -170
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,981 2,539 2,118 1,638 1,320
Total Liabilities & Shareholder's Equity 7,603 7,024 5,491 4,693 3,856
Total Common Equity 2,981 2,539 2,118 1,638 1,320
Shares Outstanding 50.90 50.40 49.70 48.90 48.20
Book Value Per Share 58.57 50.38 42.62 33.49 27.38

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Assets          
Cash & Equivalents 157 200 202 234 194
Receivables 799 801 788 752 771
Notes Receivable 0 0 0 0 0
Inventories 293 285 263 256 262
Other Current Assets 195 218 196 197 189
Total Current Assets 1,444 1,505 1,448 1,439 1,415
Net Property & Equipment 1,525 1,530 1,494 1,466 1,381
Investments & Advances 302 300 294 312 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 34 39 41 41 40
Intangibles 3,771 3,846 3,860 3,805 2,834
Deposits & Other Assets 155 155 154 148 1,340
Total Assets 7,607 7,772 7,699 7,603 7,383
Liabilities & Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Notes Payable 0 0 0 0 0
Accounts Payable 136 140 120 206 182
Current Portion Long-Term Debt 0 0 0 0 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 422 412 397 417 397
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 435 456 464 469 433
Total Current Liabilities 994 1,008 981 1,092 1,014
Mortgages 0 0 0 0 0
Deferred Taxes/Income 185 207 212 216 196
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,514 2,678 2,744 2,708 2,937
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 173 187 175 195
Minority Interest (Liabilities) 40 42 43 42 39
Total Liabilities 4,296 4,515 4,586 4,622 4,750
Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,877 1,850 1,830 1,805 1,781
Retained Earnings 1,720 1,633 1,536 1,433 1,280
Other Equity -263 -202 -234 -257 -390
Treasury Stock 24 24 19 0 38
Total Shareholder's Equity 3,311 3,258 3,114 2,981 2,633
Total Liabilities & Shareholder's Equity 7,607 7,772 7,699 7,603 7,383
Total Common Equity 3,311 3,258 3,114 2,981 2,633
Shares Outstanding 51.30 51.20 51.10 50.90 50.80
Book Value Per Share 64.54 63.62 60.94 58.57 51.83